RINVOQ
Showing 1 - 25 of 62
Disease Activity and Adverse Events of Rinvoq in Adult Moderate
Recruiting
- Ulcerative Colitis
-
Kurume-shi, Fukuoka, Japan
- +4 more
Mar 17, 2023
Application of N-of-1 Rheumatoid Arthritis
Not yet recruiting
- Arthritis, Rheumatoid
- Adalimumab
- +2 more
-
Boston, MassachusettsTufts Medical Center
Aug 24, 2023
Upadacitinib of Enthesitis Evaluated by Ultrasound in Psoriatic
Not yet recruiting
- Psoriatic Arthritis
-
Madrid, SpainInstituto de Investigación Sanitaria Fundación Jiménez Díaz
Nov 25, 2023
Ulcerative Colitis Acute Trial in Ann Arbor (Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended
Not yet recruiting
- Ulcerative Colitis Acute
- Cyclosporine Injection (IV)
- +4 more
-
Ann Arbor, MichiganUniversity of Michigan
May 6, 2023
Hidradenitis Suppurativa Trial (Upadacitinib, Placebo)
Not yet recruiting
- Hidradenitis Suppurativa
- Upadacitinib
- Placebo
- (no location specified)
May 26, 2023
Disease Activity and Adverse Events of RINVOQ in Adult
Recruiting
- Ankylosing Spondylitis
-
Kasugashi, Aichi, Japan
- +22 more
Jan 24, 2023
Juvenile Idiopathic Arthritis Trial (Upadacitinib, Tocilizumab)
Not yet recruiting
- Juvenile Idiopathic Arthritis
- (no location specified)
Nov 7, 2022
Rheumatoid Arthritis Patients Treated With JAK-inhibitor
Recruiting
- Rheumatoid Arthritis
- Upadacitinib <15 MG [Rinvoq]
-
Montpellier, FranceCHU de Montpellier
Jan 12, 2022
Oral Upadacitinib Tablets to Assess Adverse Events and Change in
Recruiting
- Rheumatoid Arthritis (RA)
- +3 more
-
Bucheon, Gyeonggido, Korea, Republic of
- +3 more
Nov 8, 2022
Rheumatoid Arthritis Trial (Upadacitinib, Adalimumab)
Not yet recruiting
- Rheumatoid Arthritis
- (no location specified)
Nov 29, 2021
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis Trial in Birmingham, Omaha (Upadacitinib, Abatacept, Secukinumab)
Recruiting
- Rheumatoid Arthritis
- +2 more
- Upadacitinib
- +7 more
-
Birmingham, Alabama
- +7 more
Sep 19, 2022
Atopic Dermatitis (AD) Trial (Upadacitinib, Placebo for Upadacitinib)
Withdrawn
- Atopic Dermatitis (AD)
- Upadacitinib
- Placebo for Upadacitinib
- (no location specified)
Apr 7, 2021
Atopic Dermatitis Trial in Norway, Puerto Rico, United States (Upadacitinib (ABT-494))
Active, not recruiting
- Atopic Dermatitis
- Upadacitinib (ABT-494)
-
Huntington Beach, California
- +17 more
Jan 25, 2023
Non-Segmental Vitiligo Trial in Worldwide (Upadacitinib, Placebo)
Active, not recruiting
- Non-Segmental Vitiligo
- Upadacitinib
- Placebo
-
Irvine, California
- +34 more
Jan 31, 2023
Hidradenitis Suppurativa (HS) Trial in Worldwide (Upadacitinib, Placebo Upadacitinib)
Completed
- Hidradenitis Suppurativa (HS)
- Upadacitinib
- Placebo Upadacitinib
-
Phoenix, Arizona
- +25 more
Mar 22, 2022
Disease Activity in Adult Ulcerative Colitis
Not yet recruiting
- Ulcerative Colitis
- (no location specified)
Aug 9, 2022
Assess Frequency Of Serious Infections In Clinical Practice In
Recruiting
- Rheumatoid Arthritis (RA)
-
Gamagori, Aichi, Japan
- +893 more
Jan 24, 2023
Disease Activity and Treatment Patterns of Upadacitinib When
Recruiting
- Psoriatic Arthritis
-
TOULOUSE Cedex 9, Haute-Garonne, France
- +33 more
Jan 25, 2023
Oral Upadacitinib Tablets to Assess Adverse Events and Change in
Not yet recruiting
- Atopic Dermatitis (AD)
- (no location specified)
Jul 17, 2023
Takayasu Arteritis (TAK) Trial in Worldwide (Upadacitinib, Placebo for Upadacitinib, Prednisolone)
Recruiting
- Takayasu Arteritis (TAK)
- Upadacitinib
- +2 more
-
Salvador, Bahia, Brazil
- +44 more
Aug 22, 2022
Assess Disease Activity in Adult Ankylosing Spondylitis Who
Recruiting
- Radiographic Axial Spondylarthritis (r-axSpA)
-
Ulm, Baden-Wuerttemberg, Germany
- +69 more
Aug 8, 2022
Disease Activity in Adolescents and Moderate to Severe
Not yet recruiting
- Atopic Dermatitis
- (no location specified)
Jul 7, 2022